← Research LibraryThe BriefFY2026 10-K · headline figures audited against SEC data
Aveanna revenue rose 20.2%, profit swung positive, and equity recovered, but debt stayed high and insiders sold heavily.
The read at a glance✓ Audited against SEC data
- Business mix — Private duty, home health, medical solutionsNote
- Revenue — Revenue rose 20.2%OK
- Profit — Net income was $225.0MOK
- Cash — Cash from ops improvedOK
- Balance sheet — Equity positive; debt $1.3BNote
- Insiders — 0 buys / 36 sellsWatch
- Accounting — Altman-Z distress; EQ safeWatch
Business
Aveanna provides home-based healthcare through Private Duty Services, Home Health and Hospice, and Medical Solutions.
Where the revenue comes from
Fiscal 2026, as Aveanna Healthcare Holdings, Inc. reports it. History and quarterly detail are in the app.
- Private Duty Services$2.0B
- Home Health And Hospice$248.6M
- Medical Solutions$183.5M
Leadership changes
From Aveanna Healthcare Holdings, Inc.'s own filings, the day they're filed.
- Sam Weil · director · departureeff. 2025-11-13
- Sheldon Retchin · Director · departureeff. 2025-03-27
- Brent Layton · director · appointmenteff. 2024-11-01
Latest filings
- 8-K · Company announcement2026-08-24
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aveanna Healthcare Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.